Genta Initiates Genasense Plus Thalidomide Trial in Myeloma

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 11
Volume 11
Issue 11

BERKELEY HEIGHTS, New Jersey-Genta Incorporated has initiated a new clinical trial with its lead anticancer drug Genasense in patients with multiple myeloma. The study will assess the safety and efficacy of Gena-sense in combination with thalidomide (Thalomid) and dexamethasone in patients who have failed standard therapy. The trial will be conducted at the University of Maryland and is sponsored by the NCI pursuant to Genta’s Cooperation Research and Development Agreement (CRADA). Genasense works by inhibiting the production of Bcl-2, a protein made by cancer cells that blocks chemotherapy-induced cell death. Genasense may enhance the effectiveness of current anticancer treatments, Genta said in a news release.

BERKELEY HEIGHTS, New Jersey—Genta Incorporated has initiated a new clinical trial with its lead anticancer drug Genasense in patients with multiple myeloma. The study will assess the safety and efficacy of Gena-sense in combination with thalidomide (Thalomid) and dexamethasone in patients who have failed standard therapy. The trial will be conducted at the University of Maryland and is sponsored by the NCI pursuant to Genta’s Cooperation Research and Development Agreement (CRADA). Genasense works by inhibiting the production of Bcl-2, a protein made by cancer cells that blocks chemotherapy-induced cell death. Genasense may enhance the effectiveness of current anticancer treatments, Genta said in a news release.

Articles in this issue
Zoledronic Acid Reduces SREs in Solid Tumors
Study Supports Wider Use of SLN Biopsy in Breast Cancer
Minorities Less Likely Than Whites to Receive Good Pain Care
Polyglutamate-Paclitaxel Controls Recurrent Ovarian Cancer
9cRA Shown to Reverse Premaliagnant Changes in Ex-Smokers
FDA Names New ODAC Chair
Neoadjuvant Weekly Paclitaxel Effective in Advanced Breast Cancer
Docetaxel Plus Gemcitabine Promising in Advanced Pancreatic Cancer
Polysaccharides Unique Targets for Immunotherapy
Genetic Fingerprinting Shows Distinct Sarcoma Subsets
Education on Increased ICP Reduces Nursing ‘Headache’
NCI Begins Trial of Spiral CT vs X-rays as a Screening Test
Good But Short-Lived Responses to Rituximab in LPHD
ODAC Supports Use of Iressa for Third-Line Therapy of NSCLC
Subcutaneous Alemtuzumab Produces High Complete Response Rate in Untreated CLL

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
A study aimed to determine the variables that correlated with extravasation rates in patients receiving radiation injection therapy.
Related Content
86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study

86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study

Hope S. Rugo, MD;Sara M. Tolaney, MD, MPH;Nancy Chan;Erika P. Hamilton, MD;Marina Sharifi;Kristine Rinn;Wassim McHayleh;Rinat Yerushalmi;Neelima Vidula, MD;Joyce O’Shaughnessy, MD;Guiseppe Curigliano;Javier Cortés, MD;Paula Muñoz Romero;Bartomeu Piza Vallespir;Kathy Puyana Theall;Alessandro Paoli;Monica Binaschi;Tomer Wasserman;Virginia Kaklamani, MD, DSc
April 25th 2025
Article
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Final analysis data from the phase 3 ALCYONE trial support using frontline daratumumab-containing regimens for those with transplant-ineligible NDMM.

Daratumumab Combo Yields Sustained Benefits in Transplant-Ineligible NDMM

Russ Conroy
April 25th 2025
Article

Final analysis data from the phase 3 ALCYONE trial support using frontline daratumumab-containing regimens for those with transplant-ineligible NDMM.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

"...The reported feasibility and activity of this combination warrant further evaluation in switch maintenance in the metastatic setting or consolidation after definite chemoradiation for patients with limited-stage SCLC," according to the study authors.

Lurbinectedin/Pembrolizumab Shows Significant Activity in Relapsed SCLC

Russ Conroy
April 25th 2025
Article

Findings from the phase 1/2 LUPER trial support further assessment of lurbinectedin plus pembrolizumab in relapsed small cell lung cancer.

Chemoradiotherapy resulted in lower incidence of local progression, prompting an evaluation of resectability in patients with advanced gallbladder cancers.

Chemoradiation Prolongs OS, Maintains QOL in Advanced Gallbladder Cancers

Roman Fabbricatore
April 24th 2025
Article

Chemoradiotherapy resulted in lower incidence of local progression, prompting an evaluation of resectability in patients with advanced gallbladder cancers.